tributyrin

DIETARY_SUPPLEMENT11 trials

Conditions

Alzheimer Disease (AD)Diabete MellitusGastro-Intestinal DisorderHealthy Overweight/ObeseHematopoietic Cell Transplantation (HCT)Parkinson DiseaseParkinson Disease DementiaProstate Cancer

Early Phase 1

Tributyrin to Promote Gut Health Among Children Undergoing Hematopoietic Cell Transplantation

WithdrawnNCT05951153

Duke UniversityHematopoietic Cell Transplantation (HCT)

Start: 2024-08-01End: 2026-11-30Updated: 2024-08-15

Phase 1

Tributyrin in Treating Patients With Refractory Prostate Cancer or Other Solid Tumors

CompletedNCT00002677

University of Maryland, BaltimoreProstate Cancer, Unspecified Adult Solid Tumor, Protocol Specific

Start: 1995-08-31End: 2003-03-31Updated: 2019-11-04

Brain Small Chain Fatty Acid Metabolism in Parkinson Disease: Tributyrin Supplementation

TerminatedNCT05446168

Nicolaas Bohnen, MD, PhDParkinson Disease

Start: 2022-07-01End: 2023-09-26Updated: 2025-01-23

Phase 2 Trial of Tributyrin in People With Parkinson's Disease and Cognitive Impairments

RecruitingNCT07154511

Prabesh KanelParkinson Disease, Parkinson Disease Dementia

Start: 2025-11-07End: 2027-05-31Target: 45Updated: 2025-11-12

Phase 3

Tributyrin Treatment in Mild Alzheimer Disease: Assessment of Butyrate Effects Via the Gut-Brain

Not yet recruitingNCT06797817

Universidad de AlmeriaAlzheimer Disease (AD)

Start: 2026-06-01End: 2029-09-02Target: 156Updated: 2025-12-18

Effect of Tributyrin Supplementation on Glycemic Control, Inflammation, and Cardiovascular Risk in Patients With Type 2 Diabetes

Not yet recruitingNCT07503548

Ain Shams UniversityDiabete Mellitus

Start: 2026-03-26End: 2026-08-26Target: 60Updated: 2026-03-31

Unknown Phase

Fat-induced Release of GLP-1 in Humans

CompletedNCT02264951

Glostrup University Hospital, CopenhagenType 2 Diabetes

Start: 2013-10-31End: 2014-02-28Updated: 2014-10-15

A Pharmacokinetic Comparison of Three Butyrate Products

CompletedNCT06700785

The Center for Applied Health Sciences, LLCGastro-Intestinal Disorder

Start: 2024-05-03End: 2024-09-12Updated: 2024-11-22

ButOx Human Trial: An Open Label Prospective Cohort Study to Investigate the Effect of Tributyrin (Butyrate Precursor Molecule) Supplementation on Markers of Calcium Oxalate Nephrolithiasis

Not yet recruitingNCT07004257

University of British ColumbiaUrolithiasis

Start: 2025-07-01End: 2028-07-01Target: 10Updated: 2025-06-04

The Metabolic Effects of Oral Tributyrin Administration

RecruitingNCT07463495

University of AarhusHealthy Overweight/Obese

Start: 2026-02-20End: 2026-12-01Target: 12Updated: 2026-03-16

A Prospective, Single-Arm Clinical Study of a Dietary Supplement for the Prevention of Acute Radiation-Induced Rectal Injury During Neoadjuvant Chemoradiotherapy for Rectal Cancer

RecruitingNCT07802002

Sixth Affiliated Hospital, Sun Yat-sen UniversityRadiation-Induced Complications, Radiotherapy

Start: 2026-07-01End: 2027-12-31Target: 23Updated: 2026-09-03

Related Papers

A Pharmacokinetic Comparison of Three Butyrate Products

Journal of Exercise and Nutrition2025-01-202 citations

The 2-monoacylglycerol moiety of dietary fat appears to be responsible for the fat-induced release of GLP-1 in humans.

2015-07-1555 citations